TY - JOUR
T1 - Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease
AU - Strohl, Anna
AU - Mori, Kristina
AU - Akers, Stacey
AU - Bshara, Wiam
AU - Buttin, Barbara
AU - Frederick, Peter J.
AU - Helenowski, Irene B.
AU - Morrison, Carl D.
AU - Odunsi, Kunle
AU - Schink, Julian C.
AU - Scholtens, Denise M.
AU - Wei, Jian Jun
AU - Kim, J. Julie
N1 - Funding Information:
We would like to acknowledge the Pathology Core Facility at Northwestern University for assistance with tissue microarray and immunohistochemistry staining. We also are grateful to Ms. Zhenxiao Lu from the Kim lab for technical assistance. This work was funded by the Rivkin Ovarian Cancer Fund (JJW).
PY - 2016/11/3
Y1 - 2016/11/3
N2 - Background: Synuclein gamma (SNCG) expression is associated with advanced disease and chemoresistance in multiple solid tumors. Our goal was to determine if SNCG protein expression in ovarian cancer was correlated with clinicopathologic variables and patient outcomes. Methods: Tissue microarrays from primary tumors of 357 ovarian, fallopian tube, and primary peritoneal cancer patients, who underwent primary surgery at Roswell Park Cancer Institute between 1995 and 2007, were immunohistochemically stained for SNCG. A pathologist blinded to patient data scored tumors as positive if ≥10 % of the sample stained for SNCG. Medical records were reviewed for clinicopathologic and demographic variables. Between the positive and negative groups, Wilcoxon rank-sum test was used to compare the median ages and Fisher’s exact test was used to compare groups in categorical variables. Cox proportional hazard models examined associations between SNCG and overall and progression-free survival. Results: The median follow-up was 36 months, median overall survival was 39 months, and median progression-free survival was 18 months. SNCG presence was associated with clinical variables of serous histology, grade 3 disease, suboptimal debulking, ascites at surgery, FIGO stage III-IV cancer, or initial CA-125 level >485. There was no significant difference in overall survival (HR 1.06 95 % CI 0.81-1.39 P 0.69) or progression-free survival (HR 1.16 95 % CI 0.89-1.50 P 0.28) for patients with or without SNCG expression. Conclusions: SNCG expression in ovarian cancer is frequent in patients with high-risk features, but it does not correlate with chemotherapy response, overall survival, or progression-free survival.
AB - Background: Synuclein gamma (SNCG) expression is associated with advanced disease and chemoresistance in multiple solid tumors. Our goal was to determine if SNCG protein expression in ovarian cancer was correlated with clinicopathologic variables and patient outcomes. Methods: Tissue microarrays from primary tumors of 357 ovarian, fallopian tube, and primary peritoneal cancer patients, who underwent primary surgery at Roswell Park Cancer Institute between 1995 and 2007, were immunohistochemically stained for SNCG. A pathologist blinded to patient data scored tumors as positive if ≥10 % of the sample stained for SNCG. Medical records were reviewed for clinicopathologic and demographic variables. Between the positive and negative groups, Wilcoxon rank-sum test was used to compare the median ages and Fisher’s exact test was used to compare groups in categorical variables. Cox proportional hazard models examined associations between SNCG and overall and progression-free survival. Results: The median follow-up was 36 months, median overall survival was 39 months, and median progression-free survival was 18 months. SNCG presence was associated with clinical variables of serous histology, grade 3 disease, suboptimal debulking, ascites at surgery, FIGO stage III-IV cancer, or initial CA-125 level >485. There was no significant difference in overall survival (HR 1.06 95 % CI 0.81-1.39 P 0.69) or progression-free survival (HR 1.16 95 % CI 0.89-1.50 P 0.28) for patients with or without SNCG expression. Conclusions: SNCG expression in ovarian cancer is frequent in patients with high-risk features, but it does not correlate with chemotherapy response, overall survival, or progression-free survival.
KW - High risk disease
KW - Ovarian cancer
KW - Synuclein gamma
UR - http://www.scopus.com/inward/record.url?scp=85009064411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009064411&partnerID=8YFLogxK
U2 - 10.1186/s13048-016-0281-4
DO - 10.1186/s13048-016-0281-4
M3 - Article
C2 - 27809878
AN - SCOPUS:85009064411
VL - 9
SP - 1
EP - 8
JO - Journal of Ovarian Research
JF - Journal of Ovarian Research
SN - 1757-2215
IS - 1
ER -